Vimta Labs reports 10% YoY growth in Q3 FY26, PAT margins hold at 17.5%
The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year
The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year
The successive PLI disbursements validate our disciplined execution and sustained commitment to strengthening India’s domestic pharmaceutical manufacturing capabilities
The early-stage trial demonstrated an excellent safety profile alongside clinically meaningful improvements in visual acuity
This license is a key regulatory milestone in advancing Hester's prevention-led poultry healthcare portfolio
The research shows 93% of global companies now cover weight-management drugs in their health insurance plans
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
Galenicum will oversee development, manufacturing and supply, while Lupin will handle regulatory submissions, approvals, and commercialization and distribution of Semaglutide across 23 countries globally
Subscribe To Our Newsletter & Stay Updated